Skip navigation


Keep up to date on AgNovos news

AgNovos Bioscience Announces 150th Patient Enrolled in RESTORE

NEW YORK, NY – AgNovos Bioscience, a medical technology company working to transform the treatment of bone disease by addressing persistent unmet needs in the care of patients, announced today that it has enrolled the 150th patient in the clinical study titled “Randomized Controlled Study of a Local Osteo-Enhancement Procedure (LOEP) to Prevent Secondary Hip Fractures in Osteoporotic Women Undergoing Treatment of Index Hip Fractures” (RESTORE). RESTORE is a randomized, controlled, prospective, single-blinded, global study designed to evaluate whether women undergoing surgical repair of a fragility hip fracture, and treated contralaterally with the AGN1 LOEP kit, are at reduced risk of a second hip fracture. The Company has activated more than 30 study sites across Japan, Germany, Spain, France, Italy, the UK, the Netherlands and Austria. RESTORE is expected to include more than 50 study sites and enroll at least 650 patients.  To learn more Click Here to read the full announcement.